Abstract library

12 results for "maintenance".
#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Côme Lepage
#1527 Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET).
Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Alexander Mc Ewan
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...
#436 Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova
#453 Activation of Hedgehog Pathway in Neuroendocrine Tumor
Introduction: Neuroendocrine tumors (NETs) are rare tumors and often follow an indolent course, especially the tumors of low-to-intermediate grade. The genetic etiology of sporadic NET is largely unknown. It is well-known that a significant number of patients with NETs may have harbored the slow-growing lesions since very a young age, suggesting it could result from alterations of pathways involved in development. Hedgehog (Hh) signaling has been found to be important in embryonic patterning, stem cell maintenance and tissue repair; and is normally silenced in most mature adult tissue. However, it frequently undergoes gain-of-function mutations or reactivation due to ligand overproduction and has been linked to the etiology of a variety of tumors.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Mei Dong
#682 Neuroendocrine Tumors, Searching for New Prognostic Biomarkers
Introduction: Neuroendocrine tumors (NET) of the digestive system were once considered relatively rare, however, the incidence is increasing. New prognostic biomarkers are needed for assessment of tumor behavior to inform patient treatment and improve outcome. The proliferation marker, Ki-67, is used for NET grading. Although classified as low grade, some tumors actually develop metastases.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Helen Miller
#1005 Role of Somatostain-Receptor Scintigraphy with SPECT-CT in Diagnosis, Staging and Follow-Up of Patients with Neuroendocrine Tumors (NETs)
Introduction: SPECT-CT study improves the certainty and accuracy of SPECT images.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Assoc. Prof. Sonya Borisova Sergieva
Keywords: SPECT-CT, Tektrotyd
#1312 Epigenetic Remodeling upon DAXX and ATRX Loss in Pancreatic Neuro-endocrine tumors (pNETs)
Introduction: DAXX and or ATRX loss occur in 40% of sporadic pNETs. DAXX and ATRX participate in the cell epigenetic status maintenance. Epigenetic changes influence gene expression, function of telomeres and genomic stability. We hypothesize that DAXX/ATRX loss drives tumor progression in pNET through epigenetic changes affecting genomic stability.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Ilaria Marinoni
Keywords: DAXX/ATRX, epigenetic, CIN
#1390 Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Liu Q, Luo J, Li C, Zhu Z H, ...
#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Dr. Markus Raderer
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.